Heather Greenlee1, Lynda G Balneaves2, Linda E Carlson2, Misha Cohen2, Gary Deng2, Dawn Hershman2, Matthew Mumber2, Jane Perlmutter2, Dugald Seely2, Ananda Sen2, Suzanna M Zick2, Debu Tripathy2. 1. Department of Epidemiology, Mailman School of Public Health (HG, DH), Herbert Irving Comprehensive Cancer Center, (HG, DH), and Department of Medicine, College of Physicians and Surgeons (DH), Columbia University, New York, NY (HG, DH); School of Nursing, University of British Columbia, Vancouver, BC, Canada (LGB); Department of Oncology, University of Calgary, Calgary, AB, Canada (LEC); Institute for Health and Aging, University of California San Francisco, CA (MC); Chicken Soup Chinese Medicine, San Francisco, CA (MC); Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (GD); Harbin Clinic, Rome, GA (MM); Gemini Group, Ann Arbor, MI (JP); Ottawa Integrative Cancer Center, Ottawa, ON, Canada (DS); Canadian College of Naturopathic Medicine, Toronto, ON, Canada (DS); Department of Family Medicine, University of Michigan Health System (AS, SMZ), Department of Environmental Health Sciences, School of Public Health (SMZ), and Department of Biostatistics (AS), University of Michigan, Ann Arbor, MI (AS, SMZ); Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (DT). hg2120@columbia.edu. 2. Department of Epidemiology, Mailman School of Public Health (HG, DH), Herbert Irving Comprehensive Cancer Center, (HG, DH), and Department of Medicine, College of Physicians and Surgeons (DH), Columbia University, New York, NY (HG, DH); School of Nursing, University of British Columbia, Vancouver, BC, Canada (LGB); Department of Oncology, University of Calgary, Calgary, AB, Canada (LEC); Institute for Health and Aging, University of California San Francisco, CA (MC); Chicken Soup Chinese Medicine, San Francisco, CA (MC); Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (GD); Harbin Clinic, Rome, GA (MM); Gemini Group, Ann Arbor, MI (JP); Ottawa Integrative Cancer Center, Ottawa, ON, Canada (DS); Canadian College of Naturopathic Medicine, Toronto, ON, Canada (DS); Department of Family Medicine, University of Michigan Health System (AS, SMZ), Department of Environmental Health Sciences, School of Public Health (SMZ), and Department of Biostatistics (AS), University of Michigan, Ann Arbor, MI (AS, SMZ); Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (DT).
Abstract
BACKGROUND: The majority of breast cancer patients use complementary and/or integrative therapies during and beyond cancer treatment to manage symptoms, prevent toxicities, and improve quality of life. Practice guidelines are needed to inform clinicians and patients about safe and effective therapies. METHODS: Following the Institute of Medicine's guideline development process, a systematic review identified randomized controlled trials testing the use of integrative therapies for supportive care in patients receiving breast cancer treatment. Trials were included if the majority of participants had breast cancer and/or breast cancer patient results were reported separately, and outcomes were clinically relevant. Recommendations were organized by outcome and graded based upon a modified version of the US Preventive Services Task Force grading system. RESULTS: The search (January 1, 1990-December 31, 2013) identified 4900 articles, of which 203 were eligible for analysis. Meditation, yoga, and relaxation with imagery are recommended for routine use for common conditions, including anxiety and mood disorders (Grade A). Stress management, yoga, massage, music therapy, energy conservation, and meditation are recommended for stress reduction, anxiety, depression, fatigue, and quality of life (Grade B). Many interventions (n = 32) had weaker evidence of benefit (Grade C). Some interventions (n = 7) were deemed unlikely to provide any benefit (Grade D). Notably, only one intervention, acetyl-l-carnitine for the prevention of taxane-induced neuropathy, was identified as likely harmful (Grade H) as it was found to increase neuropathy. The majority of intervention/modality combinations (n = 138) did not have sufficient evidence to form specific recommendations (Grade I). CONCLUSIONS: Specific integrative therapies can be recommended as evidence-based supportive care options during breast cancer treatment. Most integrative therapies require further investigation via well-designed controlled trials with meaningful outcomes.
BACKGROUND: The majority of breast cancerpatients use complementary and/or integrative therapies during and beyond cancer treatment to manage symptoms, prevent toxicities, and improve quality of life. Practice guidelines are needed to inform clinicians and patients about safe and effective therapies. METHODS: Following the Institute of Medicine's guideline development process, a systematic review identified randomized controlled trials testing the use of integrative therapies for supportive care in patients receiving breast cancer treatment. Trials were included if the majority of participants had breast cancer and/or breast cancerpatient results were reported separately, and outcomes were clinically relevant. Recommendations were organized by outcome and graded based upon a modified version of the US Preventive Services Task Force grading system. RESULTS: The search (January 1, 1990-December 31, 2013) identified 4900 articles, of which 203 were eligible for analysis. Meditation, yoga, and relaxation with imagery are recommended for routine use for common conditions, including anxiety and mood disorders (Grade A). Stress management, yoga, massage, music therapy, energy conservation, and meditation are recommended for stress reduction, anxiety, depression, fatigue, and quality of life (Grade B). Many interventions (n = 32) had weaker evidence of benefit (Grade C). Some interventions (n = 7) were deemed unlikely to provide any benefit (Grade D). Notably, only one intervention, acetyl-l-carnitine for the prevention of taxane-induced neuropathy, was identified as likely harmful (Grade H) as it was found to increase neuropathy. The majority of intervention/modality combinations (n = 138) did not have sufficient evidence to form specific recommendations (Grade I). CONCLUSIONS: Specific integrative therapies can be recommended as evidence-based supportive care options during breast cancer treatment. Most integrative therapies require further investigation via well-designed controlled trials with meaningful outcomes.
Authors: Gary E Deng; Sarah M Rausch; Lee W Jones; Amitabh Gulati; Nagi B Kumar; Heather Greenlee; M Catherine Pietanza; Barrie R Cassileth Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Barrie R Cassileth; Gary E Deng; Jorge E Gomez; Peter A S Johnstone; Nagi Kumar; Andrew J Vickers Journal: Chest Date: 2007-09 Impact factor: 9.410
Authors: Gary Deng; Andrew Vickers; Simon Yeung; Gabriella M D'Andrea; Han Xiao; Alexandra S Heerdt; Steven Sugarman; Tiffany Troso-Sandoval; Andrew D Seidman; Clifford A Hudis; Barrie Cassileth Journal: J Clin Oncol Date: 2007-12-10 Impact factor: 44.544
Authors: Sanford I Nidich; Jeremy Z Fields; Maxwell V Rainforth; Rhoda Pomerantz; David Cella; Jean Kristeller; John W Salerno; Robert H Schneider Journal: Integr Cancer Ther Date: 2009-09 Impact factor: 3.279
Authors: Suzanna M Zick; Mack T Ruffin; Julia Lee; Daniel P Normolle; Rivka Siden; Sara Alrawi; Dean E Brenner Journal: Support Care Cancer Date: 2008-11-13 Impact factor: 3.603
Authors: Jun J Mao; Karen E Wagner; Christina M Seluzicki; Audra Hugo; Laura K Galindez; Heather Sheaffer; Kevin R Fox Journal: J Oncol Pract Date: 2017-01-03 Impact factor: 3.840
Authors: Heather Greenlee; Alfred I Neugut; Laura Falci; Grace Clarke Hillyer; Donna Buono; Jeanne S Mandelblatt; Janise M Roh; Isaac J Ergas; Marilyn L Kwan; Marion Lee; Wei Yann Tsai; Zaixing Shi; Lois Lamerato; Lawrence H Kushi; Dawn L Hershman Journal: JAMA Oncol Date: 2016-09-01 Impact factor: 31.777
Authors: Gabriella M John; Dawn L Hershman; Laura Falci; Zaixing Shi; Wei-Yann Tsai; Heather Greenlee Journal: J Cancer Surviv Date: 2016-02-26 Impact factor: 4.442
Authors: Suzanne C Danhauer; Elizabeth L Addington; Stephanie J Sohl; Alejandro Chaoul; Lorenzo Cohen Journal: Support Care Cancer Date: 2017-01-07 Impact factor: 3.603
Authors: Heather Greenlee; Melissa J DuPont-Reyes; Lynda G Balneaves; Linda E Carlson; Misha R Cohen; Gary Deng; Jillian A Johnson; Matthew Mumber; Dugald Seely; Suzanna M Zick; Lindsay M Boyce; Debu Tripathy Journal: CA Cancer J Clin Date: 2017-04-24 Impact factor: 508.702